ASCO 2023 | Novel therapeutic options for PD-1 refractory melanoma

Jason Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, talks on the latest developments in the PD-1-refactory melanoma space. Lifileucel, a novel tumor infiltrating lymphocyte (TIL), and RP1, an oncolytic virus, with nivolumab are both promising treatment strategies under investigation. Dr Luke additionally highlights bispecific antibodies, as well as TCR-T cells targeting PRAME. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.